





Faecal immunochemical test EQAS schemes: IFCC FIT Working Group survey

C. Piggott¹, M. Thelen², P. Kocna³, M. Frasa⁴, S. C. Benton^{1,5}

¹NHS Bowel Cancer Screening Programme Southern Hub, Guildford, UK, ² Foundation for Quality Assessment in Medical Laboratory Diagnostics, Nijmegen, Netherlands, ³Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University, Prague, Czechia, ⁴Laboratory of Clinical Chemistry and Hematology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands, ⁵Berkshire and Surrey Pathology Services, UK

Background

Faecal immunochemical tests (FIT) for fecal haemoglobin (f-Hb) are used to triage patients for lower gastrointestinal tract investigations in colorectal cancer (CRC) screening programmes, and increasingly in patients with symptoms of CRC.

External quality assessment schemes (EQAS) enable clinical laboratories to monitor FIT performance compared with other users. EQAS for FIT exist worldwide, and though ISO standards exist, there is no guidance specifically for FIT.

Setting up EQAS to measure faecal biomarkers is challenging. Samples are collected by patients into manufacturer-specific preservative buffers, and there are many collection bottle designs with potentially different faecal mass and buffer volumes. It is challenging to establish one EQAS that resembles the FIT procedure and there is no consensus of criteria to specifically guide schemes for this test, though ISO standards [1] are available to guide best practice for EQAS.

Aim

A term of reference for the International Federation of Clinical Chemistry (IFCC) FIT Working Group was to investigate the availability and detail of FIT EQAS.

Method

A survey was designed consisting of 15 multiple choice questions about the schemes' purpose, testing environments, distribution frequencies, sample presentation, target value source, units, concentration ranges, result analyses and performance criteria.

The survey was sent to European EQA Organizers in Laboratory Medicine (EQALM), the Japanese Association of Medical Technologists (JAMT) and to other EQAS that showed FIT on websites, identified by Google searches. The survey was live during November-December 2023.

The results were collated, the percentage of each possible result calculated compared with the total number of respondents and distributed to the IFCC FIT WG for discussion.

Results

- 24 EQAS schemes offering FIT programmes were identified, though assay information was not easily available on all EQAS websites.
- There were 16 survey responses, which the IFCC FIT Working Group considered a good response. Some questions were not answered by all respondents, the reasons for this are unknown.
- A range of programmes exist covering different testing environments and different patient groups (CRC screening programmes, symptomatic testing, qualitative and quantitative testing, laboratories and point of care testing).
- There were 1-12 sample distributions per year. Results were reported in units including ng/mL, μg/L, μg/g and ng/g. The recommended units for reporting f-Hb are μg Hb/g faeces [2].
- 11 concentration ranges were covered (figure 1). There is no harmonisation of FIT methods so it is difficult to comment on the upper end of the ranges. Each user would need to establish if the range covered meets their needs.
- Faecal based samples are ideal; 69% of schemes did not provide faecal-based samples (figure 2), if faeces based then 88% did not provide samples in the bottles that patients use (figure 3). For schemes providing faecal-based samples, 63% used a generic buffer rather than each method's own sample extraction buffer, which may impact the measured result (figure 4) [3].
- For source of target values, 63% of schemes used the method group consensus (figure 5). FITs are not yet traceable to a higher order measurement standard or reference material so different numeric results can be obtained with different methods.
- Performance was reported using 5 different methods, 50% used state-of-the-art analytical goals.

Figure 1. Fit concentration ranges covered by programmes, as ng/mL and µg Hb/g faeces.




Figure 2. Are samples faecal based?




Figure 3. If faeces based, are samples in patient bottles?




Figure 4. Type of sample buffer used





Figure 5. Source of target values.



Conclusion The IFCC FIT Working Group concluded that the survey has given some useful information about EQAS for FIT, and that wide differences currently exist between schemes.

As a result of the survey the group is considering 'What does an ideal FIT EQAS look like?' and aims to provide guidance to enable schemes to be fit for purpose.

References

- 1. ISO/IEC 17043:2023 Conformity assessment general requirements for the competence of proficiency testing providers.
- 2. Fraser CG, Allison JE, Halloran SP, Young GP. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst. 104 (2012) 810-814.
- 3. Deprez L, Piggott C, van der Hagen E, Frasa M, Benton SC. Comparison and commutability study among four faecal immunochemical tests (FIT) systems. CCLM 2023;62(1):50-59.

Acknowledgements: We would like to acknowledge the members of the IFCC FIT WG for their help with formatting the survey and discussion of results, and the EQAS personnel who completed the survey.